From FT:
TechnoDerma Medicines Inc. of China is an early-stage biotech company based in the Zhejiang Province of China. The main focus of TechnoDerma is researching and developing innovative molecules for the treatment of dermatological conditions. Auspiciously, TechnoDerma’s lead program is a topical drug candidate for the treatment of androgenetic alopecia, called TDM-105795. Earlier this month, on May 10th, TechnoDerma announced that it had dosed its first two male patients in a phase 1 clinical trial for TDM-105795. From the news release, we learned that TDM-105795 is indeed a novel (new) drug being aimed at hair growth. Although TechnoDerma is based in China, its phase 1 clinical trial is being carried out by Therapeutics Inc., a contract research organization based in San Diego, CA. The trial is designed to evaluate the safety, tolerability, and pharmacokinetics (how the drug is distributed, absorbed, and excreted by the body) of TDM-105795. The TDM company website does not specifically mention what mechanism of action is targeted by its new hair loss drug.
If you live in the San Diego, CA area, you may be eligible to join the study. Starting inclusion criteria is for males ages 18-55 years old. Please let us know in the comment section if you will be attempting to join the study.
What do you think?
pubmed.ncbi.nlm.nih.gov
TechnoDerma Medicines Inc. of China is an early-stage biotech company based in the Zhejiang Province of China. The main focus of TechnoDerma is researching and developing innovative molecules for the treatment of dermatological conditions. Auspiciously, TechnoDerma’s lead program is a topical drug candidate for the treatment of androgenetic alopecia, called TDM-105795. Earlier this month, on May 10th, TechnoDerma announced that it had dosed its first two male patients in a phase 1 clinical trial for TDM-105795. From the news release, we learned that TDM-105795 is indeed a novel (new) drug being aimed at hair growth. Although TechnoDerma is based in China, its phase 1 clinical trial is being carried out by Therapeutics Inc., a contract research organization based in San Diego, CA. The trial is designed to evaluate the safety, tolerability, and pharmacokinetics (how the drug is distributed, absorbed, and excreted by the body) of TDM-105795. The TDM company website does not specifically mention what mechanism of action is targeted by its new hair loss drug.
If you live in the San Diego, CA area, you may be eligible to join the study. Starting inclusion criteria is for males ages 18-55 years old. Please let us know in the comment section if you will be attempting to join the study.
What do you think?
Thyroid receptor agonists for the treatment of androgenetic alopecia - PubMed
A thyroid hormone receptor beta subtype-selective thyromimetic 5 was found to be efficacious in both mouse and monkey hair growth models after topical applications. It penetrates the skin according to the test in human cadaver skin mounted onto Franz diffusion chambers. The serum drug level of 5...
pubmed.ncbi.nlm.nih.gov
Last edited:
